Physician

Bertrand Y Tuan, M.D.

According to 2025 Medicare claims, Bertrand Tuan, M.D. (NPI: 1578632980) practices hematology/oncology in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Francisco, CA. This provider's primary affiliated billing organization is PACIFIC HEMATOLOGY ONCOLOGY ASSOC (NPI: 1073630406; TIN: 942547219) and primary practice location at 94115-2376.

Tuan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 552 traditional Medicare patients, billed 130,844 HCPCS/CPT codes, and received $2,883,989 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,119 prescription claims across 240 beneficiaries totaling $11,317,731 in drug costs, led by Calquence (Acalabrutinib Maleate). 2023 DME data shows 24 claims. Open Payments data shows 79 records totaling $2,051. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,088,235 to $2,883,989. Similarly, Part D prescription costs have moved sharply higher in recent years, from $3,513,617 to $11,317,731. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	398	116,113	$1,088,235
2016	480	117,169	$1,270,297
2017	485	127,988	$1,199,950
2018	553	121,393	$1,301,714
2019	484	78,014	$819,261
2020	468	68,257	$952,409
2021	448	83,960	$1,310,603
2022	555	105,762	$2,119,464
2023	554	96,967	$1,932,840
2024	552	130,844	$2,883,989

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	195	1,593	$3,513,617
2016	220	1,741	$4,393,874
2017	224	1,869	$5,138,409
2018	236	1,959	$6,040,208
2019	239	2,047	$6,542,773
2020	245	2,352	$7,323,997
2021	238	2,369	$9,916,594
2022	262	2,919	$13,745,718
2023	256	2,636	$13,960,695
2024	240	2,119	$11,317,731

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	89	$18,530
2016	N/R	70	$16,114
2017	N/R	220	$19,481
2018	N/R	169	$9,024
2019	N/R	90	$1,746
2020	N/R	122	$9,096
2021	27	83	$6,397
2022	N/R	36	$1,070
2023	N/R	24	$3,822
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	87	128	$166
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	87	87	$147
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	412	845	$110
96372	Injection of drug or substance under skin or into muscle	106	402	$14
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	255	946	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	80	2,400	$1,189,654
Pomalyst	Pomalidomide	37	1,036	$827,373
Reblozyl	Luspatercept-Aamt	53	1,190	$808,303
Revlimid	Lenalidomide	41	1,148	$735,918
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	58	819	$605,710

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	79	$2,051	Takeda Pharmaceuticals U.S.A., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bertrand Y. Tuan, M.D.?

Tedicare shows public-source Medicare data for Bertrand Y. Tuan, M.D. (NPI 1578632980), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bertrand Y. Tuan, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Bertrand Y. Tuan, M.D.?

Bertrand Y. Tuan, M.D. is linked to PACIFIC HEMATOLOGY ONCOLOGY ASSOC (billing NPI 1073630406) in the available physician profile data.

Does Bertrand Y. Tuan, M.D. have Open Payments data?

Bertrand Y. Tuan, M.D. has 79 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.